Zhengye Biotechnology (NASDAQ:ZYBT) Raised to Hold at Wall Street Zen

Key Points

• Zhengye Biotechnology was upgraded to a "hold" rating by Wall Street Zen in a recent research note, indicating a change in market sentiment towards the stock.
• The stock opened at $5.30, with a 52-week range between $3.50 and $14.30, showcasing notable volatility in its performance.
• Zhengye Biotechnology specializes in veterinary vaccines, primarily focusing on livestock vaccine production and sales, based in Jilin, China.

Zhengye Biotechnology (NASDAQ:ZYBT - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a "hold" rating in a research note issued on Saturday.

Zhengye Biotechnology Stock Performance

Shares of ZYBT stock opened at $5.30 on Friday. The company's fifty day simple moving average is $6.63 and its 200-day simple moving average is $6.32. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.31 and a quick ratio of 0.88. Zhengye Biotechnology has a 52 week low of $3.50 and a 52 week high of $14.30.

Zhengye Biotechnology Company Profile

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.